Matches in SemOpenAlex for { <https://semopenalex.org/work/W4387645364> ?p ?o ?g. }
- W4387645364 endingPage "272" @default.
- W4387645364 startingPage "267" @default.
- W4387645364 abstract "BACKGROUND: Diabetic nephropathy (DN) is a complication of chronic hyperglycemia associated with diabetes mellitus (DM). Several studies have demonstrated the positive impact of sodium-glucose cotransporter-2 (SGLT2) inhibitors on kidney outcomes. The objective of the study was to evaluate the effects of dapagliflozin, an SGLT2 inhibitor, on kidney outcomes in Saudi patients with type 2 DM. MATERIALS AND METHODS: Study included all Saudi patients with type 2 DM who visited our center from August 1, 2021, to July 31, 2022, and had been on dapagliflozin for at least 3 months. Data was abstracted through chart review for all patients included in the study. Paired t-test or Wilcoxon signed-rank test were used to compare the results before and after treatment for continuous variables and the McNemar test was used to compare the results for categorical data. RESULTS: Study included 184 Saudi patients with type 2 diabetes with a mean age of 61.32 years (SD=9.37). Dapagliflozin 10 mg/day significantly reduced hemoglobin A1C (HbA1C) from a mean (SD) of 9.00 to 8.40 ( P < 0.001). Among a subgroup of patients with significant proteinuria ( n = 83), dapagliflozin significantly reduced ACR from a median of 93.1 to 64.9 mg/g ( P = 0.001). Following treatment, the estimated glomerular filtration rate improved from a mean of 69.83 to 71.68 mL/min and the mean arterial pressure (MAP) fell from 90.03 to 89.06 mmHg, both were not statistically significant. Despite a statistically insignificant increase in the episodes of urinary tract infections (UTIs), the hospitalization rate declined. No episodes of amputations or ketoacidosis occurred during the study period. CONCLUSION: SGLT2 inhibitors had beneficial effects among Saudi patients with type 2 diabetes by improving diabetic control and lowering proteinuria. Dapagliflozin did not result in significant harm, including UTIs, amputations, and ketoacidosis." @default.
- W4387645364 created "2023-10-15" @default.
- W4387645364 creator A5004984103 @default.
- W4387645364 creator A5006331699 @default.
- W4387645364 creator A5014858243 @default.
- W4387645364 creator A5022310735 @default.
- W4387645364 creator A5025709408 @default.
- W4387645364 creator A5026285885 @default.
- W4387645364 creator A5032690232 @default.
- W4387645364 creator A5036036814 @default.
- W4387645364 creator A5036423085 @default.
- W4387645364 creator A5063648201 @default.
- W4387645364 creator A5066515621 @default.
- W4387645364 creator A5084465428 @default.
- W4387645364 creator A5089385055 @default.
- W4387645364 date "2023-01-01" @default.
- W4387645364 modified "2023-10-15" @default.
- W4387645364 title "Impact of sodium-glucose cotransporter-2 inhibitors on kidney outcomes in type 2 diabetes: A tertiary center experience" @default.
- W4387645364 cites W2107709584 @default.
- W4387645364 cites W2124909544 @default.
- W4387645364 cites W2146264128 @default.
- W4387645364 cites W2157677292 @default.
- W4387645364 cites W2198388354 @default.
- W4387645364 cites W2273304042 @default.
- W4387645364 cites W2418756187 @default.
- W4387645364 cites W2588337344 @default.
- W4387645364 cites W2600135630 @default.
- W4387645364 cites W2626446274 @default.
- W4387645364 cites W2733849831 @default.
- W4387645364 cites W2757385123 @default.
- W4387645364 cites W2768576350 @default.
- W4387645364 cites W2807239802 @default.
- W4387645364 cites W2807732548 @default.
- W4387645364 cites W2894854793 @default.
- W4387645364 cites W2900236147 @default.
- W4387645364 cites W2900413769 @default.
- W4387645364 cites W2916401318 @default.
- W4387645364 cites W2937073372 @default.
- W4387645364 cites W2939222610 @default.
- W4387645364 cites W2939633281 @default.
- W4387645364 cites W2948520814 @default.
- W4387645364 cites W2965440006 @default.
- W4387645364 cites W2985096072 @default.
- W4387645364 cites W2999314916 @default.
- W4387645364 cites W3005132271 @default.
- W4387645364 cites W3011801097 @default.
- W4387645364 cites W3014721260 @default.
- W4387645364 cites W3022616650 @default.
- W4387645364 cites W3022667718 @default.
- W4387645364 cites W3033374042 @default.
- W4387645364 cites W3046103843 @default.
- W4387645364 cites W3097772902 @default.
- W4387645364 cites W3119081787 @default.
- W4387645364 cites W3121105072 @default.
- W4387645364 cites W3132155644 @default.
- W4387645364 cites W3135472915 @default.
- W4387645364 cites W3154796681 @default.
- W4387645364 cites W3158420766 @default.
- W4387645364 cites W4226263934 @default.
- W4387645364 cites W4282932323 @default.
- W4387645364 cites W4311988274 @default.
- W4387645364 cites W4319262291 @default.
- W4387645364 doi "https://doi.org/10.4103/jfcm.jfcm_111_23" @default.
- W4387645364 hasPublicationYear "2023" @default.
- W4387645364 type Work @default.
- W4387645364 citedByCount "0" @default.
- W4387645364 crossrefType "journal-article" @default.
- W4387645364 hasAuthorship W4387645364A5004984103 @default.
- W4387645364 hasAuthorship W4387645364A5006331699 @default.
- W4387645364 hasAuthorship W4387645364A5014858243 @default.
- W4387645364 hasAuthorship W4387645364A5022310735 @default.
- W4387645364 hasAuthorship W4387645364A5025709408 @default.
- W4387645364 hasAuthorship W4387645364A5026285885 @default.
- W4387645364 hasAuthorship W4387645364A5032690232 @default.
- W4387645364 hasAuthorship W4387645364A5036036814 @default.
- W4387645364 hasAuthorship W4387645364A5036423085 @default.
- W4387645364 hasAuthorship W4387645364A5063648201 @default.
- W4387645364 hasAuthorship W4387645364A5066515621 @default.
- W4387645364 hasAuthorship W4387645364A5084465428 @default.
- W4387645364 hasAuthorship W4387645364A5089385055 @default.
- W4387645364 hasBestOaLocation W43876453641 @default.
- W4387645364 hasConcept C105795698 @default.
- W4387645364 hasConcept C126322002 @default.
- W4387645364 hasConcept C126894567 @default.
- W4387645364 hasConcept C134018914 @default.
- W4387645364 hasConcept C159641895 @default.
- W4387645364 hasConcept C186282968 @default.
- W4387645364 hasConcept C2777180221 @default.
- W4387645364 hasConcept C2777422806 @default.
- W4387645364 hasConcept C2777448766 @default.
- W4387645364 hasConcept C2778653478 @default.
- W4387645364 hasConcept C2780306776 @default.
- W4387645364 hasConcept C2910068830 @default.
- W4387645364 hasConcept C33923547 @default.
- W4387645364 hasConcept C555293320 @default.
- W4387645364 hasConcept C71924100 @default.
- W4387645364 hasConcept C90924648 @default.
- W4387645364 hasConceptScore W4387645364C105795698 @default.